ReachMD

Episodes 1-15 of 46

• • 

    

    Marianne J. Davies, DNP, ACNP, AOCNP

    Peer

  • 

    

    Julie R. Brahmer, MD, MSc

    Peer

  0

  

  RestartResume

  Addressing Barriers in Managing IRAEs Associated with Immune Checkpoint Inhibitor Therapy

  0.25 credits

• • 

    

    Timothy Fenske, MD, MS

    Peer

  0

  

  RestartResume

  Part 2: Improving Risk-based Management Decisions in Follicular Lymphoma

  0.50 credits

• • 

    

    Timothy Fenske, MD, MS

    Peer

  0

  

  RestartResume

  Part 1: Improving Risk-based Management Decisions in Follicular Lymphoma

  0.50 credits

• • 

    

    Ruben A. Mesa, MD, FACP

    Peer

  0

  

  RestartResume

  Part 2: Improving Quality of Care and Shared Decision-Making in Myelofibrosis

  0.50 credits

• • 

    

    Ruben A. Mesa, MD, FACP

    Peer

  1

  

  RestartResume

  Part 1: Improving Quality of Care and Shared Decision-Making in Myelofibrosis

  0.50 credits

• • 

    

    Robert Mocharnuk, MD

    Peer

  • 

    

    Richard S. Finn, MD

    Peer

  • 

    

    Amit Singal, MD, MS

    Peer

  2

  

  RestartResume

  Multidisciplinary Perspectives in Advanced HCC:  A Focus on Immune Checkpoint Inhibitors

  0.75 credits

• • 

    

    Karen Reckamp, MS, MD

    Peer

  • 

    

    Heather Wakelee, MD

    Peer

  1

  

  RestartResume

  Optimizing Patient Outcomes in Advanced NSCLC in a Rapidly Evolving Treatment Era

  1.00 credits

• • 

    

    Karen Reckamp, MS, MD

    Peer

  • 

    

    Heather Wakelee, MD

    Peer

  3

  

  RestartResume

  Optimizing Patient Outcomes in Advanced NSCLC in a Rapidly Evolving Treatment Era: A Video-based Patient Case Series

  0.50 credits

• • 

    

    Robert Mocharnuk, MD

    Peer

  • 

    

    Hossein Borghaei, MS, DO

    Peer

  5

  

  RestartResume

  Part II: Precision Medicine in NSCLC—Implications for Molecular Testing and Treatment

  0.50 credits

• • 

    

    Benjamin O. Anderson M.D.

    Peer

  0

  

  RestartResume

  Adapting Breast Cancer Care Amid COVID-19

• • 

    

    Scott Kopetz, MD, PhD

    Peer

  • 

    

    Prof Eric Van Cutsem, MD, PhD

    Peer

  • 

    

    Josep Tabernero, MD, PhD

    Peer

  3

  

  RestartResume

  Optimizing Treatment Selection in BRAF V600E-Mutated Metastatic Colorectal Cancer

  0.25 credits

• • 

    

    Scott Kopetz, MD, PhD

    Peer

  • 

    

    Prof Eric Van Cutsem, MD, PhD

    Peer

  2

  

  RestartResume

  Latest Clinical Advances in the Treatment of BRAF V600E-Mutated Metastatic Colorectal Cancer

  0.25 credits

• • 

    

    Richard T. Penson, MD, MRCP

    Peer

  • 

    

    Linda R. Duska, MD, MPH

    Peer

  11

  

  RestartResume

  Keeping Pace in Women’s Cancer: Focus on Endometrial Carcinoma

  0.25 credits

• • 

    

    Mark A. Socinski, MD

    Peer

  • 

    

    Alexander Drilon, MD

    Peer

  8

  

  RestartResume

  Keeping Pace: Advances in RET Fusion-Positive NSCLC

  0.25 credits

• • 

    

    Sara Hurvitz, MD

    Peer

  • 

    

    Jacob Sands, MD

    Peer

  8

  

  RestartResume

  Clinical Considerations for Targeted Therapies Across Multiple Tumor Types

  0.25 credits

• 1
• 2
• 3
• 4
• Next